Filing Details

Accession Number:
0001127602-20-029221
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-11-17 15:25:48
Reporting Period:
2020-11-16
Accepted Time:
2020-11-17 15:25:48
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
816956 Conmed Corp CNMD Electromedical & Electrotherapeutic Apparatus (3845) 160977505
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1635424 M Terence Berge C/O Conmed Corporation
525 French Road
Utica NY 13502
Vp-Corporate Controller No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-11-16 3,600 $51.30 23,635 No 4 M Direct
Common Stock Disposition 2020-11-16 2,723 $98.21 20,912 No 4 F Direct
Common Stock Acquisiton 2020-11-16 6,400 $39.87 27,312 No 4 M Direct
Common Stock Disposition 2020-11-16 6,400 $96.29 20,912 No 4 S Direct
Common Stock Disposition 2020-11-16 5,000 $96.35 15,912 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Sars (Stock Appreciation Rights) Disposition 2020-11-16 3,600 $0.00 3,600 $51.30
Common Stock Options To Purchase Common Stock Disposition 2020-11-16 6,400 $0.00 6,400 $39.87
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2025-02-27 No 4 M Direct
12,900 2026-03-01 No 4 M Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.24 to $96.31. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
  2. The stock appreciation rights ("SARs") were granted under the Company's 1999 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts (20%) over a five year period.
  3. The stock options were granted under the Company's 2015 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts over a five year period